| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective September 30, 2018, Susan E. Graf, Chief Business Officer of Epizyme, Inc. (the “Company”) will be leaving the Company to pursue other business opportunities. In connection with her departure from the Company, Ms. Graf will be eligible to receive post-separation benefits under the terms of the Company’s Executive Severance and Change in Control Plan, together with certain other benefits, including apro-rated bonus.
Suzanne Fleming, the Company’s Senior Vice President, Finance, Treasurer and principal accounting officer has been appointed the Company’s principal financial officer. Ms. Fleming, 57, has served as the Company’s Senior Vice President, Finance and Treasurer since she joined the Company in September 2017. Prior to joining the Company, from October 2014 to September 2017, Ms. Fleming served as Vice President, Finance for Foundation Medicine, Inc., a molecular information company focused on cancer care, where she was responsible for accounting, financial reporting, and compliance. Prior to joining Foundation Medicine, Ms. Fleming spent over 25 years in a number of finance leadership roles where she also was responsible for accounting, financial reporting, and compliance, including Chief Accounting Officer for Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on rare diseases, from August 2013 to October 2014, and Vice President, Finance for AVEO Oncology, Inc., a biopharmaceutical company focused on targeted therapeutics for oncology, from November 2005 to August 2013. Ms. Fleming received a Bachelor of Science in Business Administration from Stonehill College, and is a Certified Public Accountant.
| Item 7.01 | Regulation FD Disclosure. |
In connection with Ms. Graf’s departure from the Company, the Company has conducted a reorganization of its management. Matthew E. Ros, currently Chief Operating Officer, will move into the role of Chief Strategy & Business Officer, overseeing the corporate strategy and business functions, inclusive of the finance, business development, communications, and commercial functions. Mr. Ros has served as the Company’s Chief Operating Officer since May 2016. Prior to joining the Company, from September 2010 to May 2016, Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company, most recently as Chief Operating Officer/Global Head of the Oncology Business unit from December 2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014. From October 2007 to June 2010, Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in Bristol-Myers Squibb’s Oncology Division, serving in roles with increasing responsibility from 1990-2007. He received a Bachelor of Science from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for theNon-Financial Manager at Wharton School of the University of Pennsylvania.
Dr. Shefali Agarwal, the Company’s Chief Medical Officer appointed in July 2018, is responsible for Clinical Operations, Medical, Pharmacovigilance, Translational Medicine and Clinical Pharmacology. With the reorganization, Dr. Agarwal will also now oversee Medical Affairs and Program and Portfolio Management. Dr. Agarwal has held leadership positions across medical research, clinical development, clinical operations and medical affairs, and has led clinical and regulatory engagements for small molecules, biologics, liposomal and cell therapy products from preclinical research work through registration filings. Prior to joining the Company. Dr. Agarwal served as chief medical officer at SQZ Biotech, where she built and led the clinical development organization, inclusive of Clinical Research Operations and Regulatory. She has held leadership positions at Curis, where she oversaw the Phase 2 study for its dual HDAC/PI3K inhibitor in diffuse largeB-cell lymphoma and the Phase 1 study in solid tumors for its oral checkpoint inhibitor, and Tesaro, where she led the U.S. and European marketing authorization submissions for ZEJULA® (niraparib) in ovarian cancer. She has also held positions of increasing responsibility at Covidien, AVEO Oncology and Pfizer. Dr. Agarwal received her MBBS medical degree from Karnataka University’s Mahadevappa Rampure Medical School in India, Master’s Degree in Public Health from Johns Hopkins University, where she led clinical research in the Department of Anesthesiology and Critical Care Medicine, and a Master of Science degree in Business from the University of Baltimore’s Merrick School of Business.
